ALSO NOTED: Allergan buying Groupe Corneal; GSK agrees to pay $63M settlement; and much more...

> Irvine, CA-based Allergan is buying France's Groupe Corneal Laboratoires for $216 million in cash. Allergan, which makes Botox, plans to separate the French companies' aesthetic and ophthalmic business with an eye to selling the ophthalmic division. Allergan also reported an increase in third quarter revenue due largely to the sale of products from the Inamed buyout. Report [1]

> TopoTarget will gain $2.6 million up front for a deal in which LEO Pharma will commercialize an inhibitor for dermatological disorders it had developed with CuraGen. Release [2]  

> GlaxoSmithKline has agreed to pay $63.8 million to settle a class action suit that it promoted Paxil while failing to disclose negative data about the drug's efficacy and safety. GSK said it wanted to settle the suit to avoid more litigation costs. Report [3]

> Citing new "strategic priorities," Par Pharmaceutical [4] announced that Valeant [5] had terminated its promotion deal for the antiemetic Cesamet. Report [6]

And Finally... Scientists at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied treatment for the eye cancer retinoblastoma. Release [7]